This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Dermatology  • Melanoma  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Monica M. Madray, MD; John F. Greene Jr, MD; David F. Butler, MD

Arch Neurol. 2008;65(10):1378-1379.

Objective  To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.

Design  Case report.

Setting  Dermatology outpatient clinic.

Patient  A 33-year-old white woman developed an erythematous nodule on her leg 4 months after starting treatment with glatiramer acetate. Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma. Further evaluation showed no systemic involvement.

Intervention  Radiation therapy induced a complete remission.

Conclusions  Several T-cell–mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum. We report the association of a T-cell malignancy with the use of glatiramer acetate.

Author Affiliations: Departments of Dermatology (Drs Madray and Butler) and Pathology (Dr Greene), Scott and White Memorial Hospital and Clinic, Temple, Texas.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?